1. Steven Fuller, Michael Lebowitz, Solomon Stewart, Susan Walker, Hossein Ghanbari, Allan Bohlke, Scott Burton, Leonard Chu, Vinh Hua.  “Enhanced immunogenicity of a nanoparticle therapeutic cancer vaccine targeting HAAH delivered intradermally using 3M’s hollow microstructured transdermal system (hMTS).” [Poster].  In: Proceedings of the 30th Annual Meeting of Society for Immunotherapy of Cancer.  2015 Nov 4-8; National Harbor, MD.  Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P433.  (2015)
  2. Michael Lebowitz, Solomon Stewart, Susan Walker, Samindhi Wu, Steven Fuller, Hossein Ghanbari.  “A nanoparticle therapeutic vaccine targeting HAAH stimulates cellular immunity.”  [Poster].  In:  Proceedings of the 30th Annual Meeting of Society for Immunotherapy of Cancer.  2015 Nov 4-8; National Harbor, MD.  Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P442.  (2015)
  3. Ghanbari, H. A., Jiang, Z-G, Fuller, S. A.  “A Cancer Therapeutic Nanoparticle Vaccine Targeting Human Aspartyl (Asparaginyl) b-Hydroxylase.”  BIT’s 7th Annual World Congress of Vaccine-2015, Nanjing, China.  (2015)
  4. Fuller, S, Lebowitz, M, Stewart, S. “A cancer therapeutic nanoparticle vaccine targeting HAAH significantly inhibits metastasis in a mouse model of breast cancer.” [Poster]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA.  Abstract #4288.  (2015)
  5. Dong X, Lin Q, Aihara A, Li Y, Huang CK, Chung W, Tang Q, Chen X, Carlson R, Nadolny C, Gabriel G, Olsen M, Wands JR.  “Aspartate b-Hydroxylase Expression Promotes a Malignant Pancreatic Cellular Phenotype.” Oncotarget. 6(2):1231-48, 2015.
  6. Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR.  “Aspartate-b-hydroxylase Induces Epitope-specific T Cell Responses in Hepatocellular Carcinoma.”  Vaccine.33(10):1256-66, 2015.
  7. Fuller, S, Lebowitz, M, Stewart, S, Ghanbari, H.  “A cancer therapeutic nanoparticle vaccine targeting HAAH improves 3-week survival from 12.5% to 100% in a mouse model of metastatic breast cancer.”  [Poster].  In:  Proceedings of the 29th Annual Meeting of Society for Immunotherapy of Cancer; 2014 Nov 6-9; National Harbor, MD.  Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P52.  (2014)
  8. Semenuk, MA, Ghanbari, EB, Lebowitz, MS, Ghanbari, HA.  “Quantitative recovery of aspartyl (asparaginyl) beta hydroxylase (HAAH) from an exosomal fraction of human sera from cancer patients.”  [Poster B83] AACR Meeting, December 1-4, 2014.  Orlando, FL (2014)
  9. A. Aihara, C-K Huang, M. J. Olsen, Q. Lin, W. Chung, Q. Tang, X. Dong, J R. Wands.  “A Cell-Surface b-Hydroxylase Is a Biomarker and Therapeutic Target for Hepatocellular Carcinoma”, Hepatology, Vol 60:4, pp 1302-1313, 2014.
  10. Fuller, S, Stewart, S, Lebowitz, M, Malhotra, K, Ghanbari, H.  “Inhibition of tumor growth in vivo by a nanoparticle-based therapeutic cancer vaccine targeting HAAH.”  [Poster].  In:  Proceedings of the 28th Annual Meeting of Society for Immunotherapy of Cancer; 2013 Nov 8-10; National Harbor, MD.  Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P269.  (2013)
  11. Biswajit, B, Stewart, S, Malhotra, K, Lebowitz, M, Fuller, S, Merril, C, Ghanbari, H.  “Design, development and production of nano-particle-based anticancer vaccine targeting human aspartyl (asparaginyl) beta-hydroxylase (HAAH).”  [Poster].  In:  Proceedings of the 28th Annual Meeting of Society for Immunotherapy of Cancer; 2013 Nov 8-10; National Harbor, MD.  Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P201.  (2013)
  12. Fuller, S, Stewart, S, Lebowitz, M, Malhotra, K, Semenuk, M, Biswas, Biswajit, Ghanbari, H.  “Immunogenicity of a lambda phage-based anti-cancer vaccine targeting HAAH.”  [Poster].  In:  Proceedings of the 28th Annual Meeting of Society for Immunotherapy of Cancer; 2013 Nov 8-10; National Harbor, MD.  Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P210.  (2013)
  13. Moshiri, M., Moshiri, K., Lebowitz, M. S., Repoli, A. F., Semenuk, M., Bensmail, I., Ghanbari, H. A.  “Early Diagnosis of Cancer, HAAH (Human Aspartyl (Asparaginyl) β-Hydroxylase) a predictive Biomarker, A Serum Immunoassay and Personalized Medicine.”  BIT’s 3rd Annual World Congress of MolMed-2013, Haikou, China (2013)
  14. Moshiri, M., Moshiri, K., Ghanbari, H. A., Semenuk, M., Repoli, A. F., Lebowitz, M. S.  “An Immunoassay for Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH), A Novel Colon Cancer Serum Biomarker: Personalized Diagnosis and Management of Colon Cancer.”  BIT’s 3rd Annual World Congress of MolMed-2013, Haikou, China (2013)
  15. Moshiri, M., Moshiri, K., Semenuk, M., Repoli, A. F., Lebowitz, M. S., Harris, P. J., Ghanbari, H. A.  “HAAH (Human Aspartyl (Asparaginyl) b-Hydroxylase), A Serum Biomarker for Lung Cancer.”  BIT’s 3rd Annual World Congress of MolMed-2013, Haikou, China (2013)
  16. Semenuk, M. A., Ghanbari, H. A.  “Serum Biomarkers Carcinoembryonic Antigen (CEA) and Human Aspartyl (Asparaginyl) b-Hydroxylase (HAAH) Compared in Normal Volunteers, Smokers, and Stage I/II Lung Cancer Patients.”  AACR Annual Meeting 2013, Washington, DC (2013)
  17. Moshiri, M., Lebowitz, M. S., Roberts, S. F., Zokaei-Ashtiani, A., Ghanbari, H.  “Cancer Biomarker, HAAH (Human Aspartyl (Asparaginyl) β-Hydroxylase), a Companion Diagnostic Strategy.”  Global Technology Community: 2nd Biomarkers Europe Summit, Zurich, Switzerland (2012)
  18. Moshiri, M., Lebowitz, M.S., Roberts, S.F., Zokaei-Ashtiani, A. Ghanbari, H.  “HAAH (Human Aspartyl (Asparaginyl) beta-Hydroxylase), a Cancer Tumor Marker, as Companion Diagnostic Strategy.”  BIT’s 2nd World Congress of MolMed-2012.  Guangzhou, China (2012)
  19. Moshiri, M., Lebowitz, M.S., Roberts, S.F., Zokaei-Ashtiani, A. Ghanbari, H.  “Human Aspartyl (Asparaginyl) beta-Hydroxylase (HAAH) Levels as an Indicator for Patients at Risk for Prostate Cancer.”  BIT’s 2nd World Congress of MolMed-2012.  Guangzhou, China (2012)
  20. Mahmood Moshiri, Michael S. Lebowitz, Steve F. Roberts, Chandra J. Panchal, and Hossein A. Ghanbari. “Early Diagnosis Of Cancer: HAAH-based Serum Immunoassay.”  UICC World Cancer Congress, Montreal, Canada (2012)
  21. Hossein Ghanbari, Michael S. Lebowitz, Chandra Panchal and Mahmood Moshiri. “HAAH-based Monitoring of Cancer Remission / Recurrence.” UICC World Cancer Congress, Montreal, Canada (2012)
  22. M. Shimoda, Y. Tomimaru, K. P. Charpentier, H. Safran, R. I. Carlson, J. Wands.  “Tumor progression-related transmembrane protein aspartate-b-hydroxylase is a target for immunotherapy of hepatocellular carcinoma”, Journal of Hepatology, Vol 55, pp 1129-1135, 2012.
  23. T. Noda, M. Shimoda, V. Oritz, A. e. Sirica, J. R. Wands.  “Immunization with Aspartate-b-Hydroxylase–-Loaded Dendritic Cells Produces Antitumor Effects in a Rat Model of Intrahepatic Cholangiocarcinoma”, Hepatology, Vol 55:1, pp 86-97, 2012.
  24. Biswajit Biswas, Marjan Alaghmand, Ilham Bensmail, Carl Merril, and Hossein A. Ghanbari. “Dendritic Cell-Based Cancer Therapeutic Vaccine Targeting HAAH Using Nano-Particles To Overcome Tolerance and Avoid Auto-Immune Response.” International Society for Biological Therapy of Cancer (iSBTc) 25th Annual Meeting, Washington, DC (2010)
  25. Lawton M, Tong M, Gundogan F, Wands JR, de la Monte SM, “Aspartyl-(asparaginyl) beta-hydroxylase, hypoxia-inducible factor-alpha and Notch cross-talk in regulating neuronal motility.” Oxid Med Cell Longev. 3(5):347-56, 2010.
  26. D. Khayat, R. Mouawad, M. S. Lebowitz, and H. A. Ghanbari. “Serum HAAH Level in NSCLC is a Diagnostic and Could be a Predictive Factor of Clinical Response.”  44th ASCO Annual Meeting, Chicago, IL (2008)
  27. Ilham Bensmail, Michael S. Lebowitz and Hossein A. Ghanbari.  “Anti-HAAH antibodies block leukemic cell activity via down-regulation of the Notch signaling pathway.”  AACR Annual Meeting 2008, San Diego, CA (2008)
  28. Hossein A. Ghanbari and Michael S. Lebowitz.  “In vivo efficacy of PAN-622: An All Human Sequence Monoclonal Antibody Targeted at HAAH.”  AACR Annual Meeting 2008, San Diego, CA (2008)
  29. S.N. Keith, A.F. Repoli, M. Semenuk, P.J. Harris, H.A. Ghanbari and M.S. Lebowitz.  “HAAh identifies prostate cancer, regardless of PSA level.” 19th World Congress:  International Congress on Anti Cancer Treatment, Paris, France (2008)
  30. Hossein Ghanbari, Angela F. Repoli, Mark Semenuk, Ilham Bensmail, Audrey A. Vasauskas and Michael S. Lebowitz. “HAAH-based Serum Cancer Test: A Companion Diagnostic in Cancer Therapeutics.”  International Congress on Anti Cancer Treatment, Paris, France. (2008)
  31. Hossein Ghanbari, Valery Nelson, Angela F. Repoli, and Michael S. Lebowitz. “PAN-622, An All-Human Anti-Cancer Antibody Drug Candidate Targeted to HAAH: A Cytostatic Approach to Cancer Therapy.  International Congress on Anti Cancer Treatment, Paris, France. (2008)
  32. Michael S. Lebowitz, Angela F. Repoli, Mark Semenuk, Ilham Bensmail and Hossein A. Ghanbari. “Integration of the Cancer Biomarker, HAAH, into a Companion Diagnostic Strategy.” Oncology Biomarkers: From Discovery to Validation. San Francisco, CA (2008)
  33. J.J. Carter, M. Tong, E. Silbermann, S.A. Lahousse, F.F. Ding, L. Longato, N. Roper, J.R. Wands, and S. M. de la Monte. “Ethanol Impaired Neuronal Migration is Associated with Reduced Aspartyl-Asparaginyl-β-Hydroxylase Expression.” Acta Neuropathol, 116, 303-315, 2008.
  34. F. Gundogan, G. Elwood, L. Longato, M. Tong, A. Feijoo, R.I., Carlson, J.R. Wands and S.M. de la Monte. “Impaired Placentation in Fetal Alcohol Syndrome.” Placenta, 29, 148-157, 2008.
  35. H.A. Ghanbari, A.F. Repoli, M. Semenuk, P.J. Harris and M.S. Lebowitz. “HAAH as a serum biomarker for colorectal cancer.”  An AACR Special Conference in Cancer Research―Advances in Colon Cancer Research Cambridge, MA (2007)
  36. Ghanbari, HA; Repoli, AF; Semenuk, M; Harris, PJ; Lebowitz, MS.  “HAAH as a Serum Biomarker for Breast Cancer.”  An AACR Special Conference in Cancer Research―Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San Diego, CA (2007) 
  37. Semenuk, M; Repoli, AF; Lebowitz, MS; Harris, PJ; Ghanbari, HA.  “HAAH is a Serum Biomarker for Lung Cancer.”  The Second Annual AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment, Atlanta, GA (2007)
  38. Yeung, YA, Finney, AH, Koyrakh, IA, Lebowitz, MS, Wands, JR, Ghanbari, HA, Wittrup, KD:  “Isolation and Characterization of Human Antibodies Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase.” Human Antibodies. 16:163-176, (2007).
  39. D’Amico, MD; Roberts, SF; Lebowitz, MS; Ghanbari, HA. “Use of anti-HAAH antibodies in cancer therapy: specific delivery of cytotoxic agents.”  AACR Annual Meeting 2007, Los Angeles, CA (2007)
  40. Otahalova, E., Lebowitz, M.S., Ghanbari, H.A. “Identification of Responders and Non-Responders to Imatinib Prior to Treatment.”  18th  EORTC-NCI-AACR International Conference on “Molecular Targets and Cancer Therapeutics, Prague, Czech Republic (2006)
  41. Ghanbari, H.A., Vasauskas, A.A., Bensmail, I., Lebowitz, M.S. “HAAH is a Serum Biomarker for Prostate Cancer.” 1st AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL (2006)
  42. Lebowitz, M.S., Otahalova, E., Ghanbari, H.A. “A Novel Biomarker to Diagnose and Monitor Acute Myelogenous Leukemia.”  1st AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL (2006)
  43. Nelson, V.M., Finney, A.H., Drape, R.J., Bleck, G.T., Lebowitz, M.S., Ghanbari, H.A. “Manufacture of anti-HAAH Antibodies as Potential Human Therapeutics.” 1st AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL (2006)
  44. A.H. Finney, M.W. D’Amico, S.F. Roberts, M.S. Lebowitz, H.A. Ghanbari.  Surface Expressed HAAH in Cancer Cells is an Internalizing Antigen. AACR 97th Annual Meeting, Washington, D.C. 2006
  45. Stephanie A. Lahousse, Jade J. Carter, Xaolai J. Xu, Jack R. Wands and Suzanne M. de la Monte.  “Differential growth factor regulation of Aspartyl-Asparagyl β hydroxylase family genes in SH-Sy5y human neuroblastoma cells.” BMC Cell Biology, 7:41, 1-21, 2006.
  46. M.Chiara Cantarini, Suzanne M. De la Monte, Maoyin Pang, Ming Tong, Antonia D’Errico, Franco Trevisani and Jack R. Wands. “Aspartyl-Asparagyl β hydroxylase Over-Expression in Human Hepatoma is Linked to Activation of Insulin-Like Growth Factor and Notch Signaling Mechanisms.” Hepatology, 44:2, 446-457, 2006.
  47. Suzanne M. de la Monte, Seishu Tamaki, M. Chiara Cantarini, Nedim Ince, Marcus Wiedmann, Jade J. Carter, Stephanie A. Lahousse, Sophia Califano, Takashi Maeda, Takato Ueno, Antonia D’Errico, Franco Trevisani, Jack R. Wands.  “Aspartyl-(asparaginyl)-β-hydroxylase Regulates Hepatocellular Carcinoma Invasiveness.” Journal of Hepatology: 44, 971-983, 2006.
  48. Ghanbari, H.A. “Cancer Diagnostics Integrated With Therapeutics: A Comprehensive Approach to Managing the Disease.” Journal of Biomedicine and Biotechnology, 2004:4; 175-176. (2004)
  49. Takashi Maeda, Ken-ichi Taguchi, Shin-ichi Aishima, Mitsuo Shimada, Deborah Hintz, Nicholas LaRusso, Gregory Gores, Masazumi Tsuneyoshi, Keizo Sugimachi, Jack R. Wands, and Suzanne de la Monte. “Clinicopathological Correlates of Aspartyl (Asparaginyl) β-Hydroxylas Over-Expression in Cholangiocarcinoma.” Cancer Detection and Prevention: 28, 313-318, 2004.
  50. Eric P. Berthiaume, M.D., and Jack Wands, M.D. “The Molecular Pathogenesis of Cholangiocarcinoma.” Seminars in Liver Disease 24(2): 127-137, 2004.
  51. Yeung, A., Finney, A.H., Lebowitz, M.S., Ghanbari, K., Ghanbari, H.A., Wittrup, D.: “Isolation and Engineering of Biologically Active Human Single-Chain Antibody Fragments (Scfv) Against Human Aspartyl (Asparaginyl) β-Hydroxylase.” AACR—Molecular Targets and Cancer Therapeutics Meeting,  November 17-21, 2003, Boston, MA
  52. Finney, A.H., Lebowitz, M.S., Vasauskas, A.A., Ghanbari, K., Nelson, V.M., and Ghanbari, H.A.: “Anti-Proliferative and Anti-Metastatic Activities of Monoclonal Antibodies to Human Aspartyl (Asparaginyl) β-Hydroxylase.” AACR—Molecular Targets and Cancer Therapeutics Meeting, November 17-21, 2003, Boston, MA.
  53. Vasauskas, A.A., Glass, L., Ghanbari, K., Lebowitz, M.S., Ranji, C., Maric, M., and Ghanbari, H.A.: “HAAH as a Biomarker for Pancreatic Adenocarcinoma Using IHC, qRT-PCR and ELISA.” AACR—Molecular Targets and Cancer Therapeutics Meeting, November 17-21, 2003, Boston, MA.
  54. Audrey A. Vasauskas, Cyra M. Ranji, Kasra Ghanbari, Michael S. Lebowitz, and Hossein A. Ghanbari. Human Aspartyl (Asparaginyl) β-Hydroxylase is a Serum Biomarker of Breast, Ovarian, and Prostate Cancer. AACR 94th Annual Meeting, July 11-14 2003, Washington, DC. 
  55. Lawrence Glass, Kasra Ghanbari, Michael S. Lebowitz, and Hossein A. Ghanbari. Differential Expression of ASPH Gene Encoding Human Aspartyl (Asparaginyl) β-Hydroxylase in Cancer Versus Normal Tissues. AACR 94th Annual Meeting, July 11-14 2003, Washington, DC. 
  56. Takashi Maeda, Paul Sepe, Stephanie Lahousse, Seishu Tamaki, Munetomo Enjoji, Jack R. Wands, and Suzanne M. de la Monte.  “Antisense Oligodeoxynucleotides Directed Against Aspartyl (Asparaginyl) b-Hydroxylase Suppress Migration Of Cholangiocarcinoma Cells.”  Journal of Hepatology: 38, 615-622, 2003.
  57. Palumbo KS, Wands JR, Safran H, King T, Carlson RI, de la Monte SM. “Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma.” Pancreas Jul; 25(1):39-44, 2002.  
  58. Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, de la Monte SM. “Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility.” Lab Invest J: 82(7):881-91, 2002.
  59. Michael S. Lebowitz, Angela H. Finney, Valery M. Nelson, Audrey A. Vasauskas, Kasra Ghanbari, Alan H. Deutch and Hossein A. Ghanbari. Inhibition of Cancer Cell Proliferation, Motility and Invasiveness by Monoclonal Antibodies Specific for Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH). AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, October 29-November 2, 2001, Miami Beach, Florida.
  60. Michael A. Rosen, Kasra Ghanbari, Alan H. Deutch, and Hossein A. Ghanbari. Development of Cancer Immunodiagnostics Using Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) as a Biomarker. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, October 29-November 2, 2001, Miami Beach, Florida. 
  61. Nedim Ince, Suzanne de la Monte, Jack R. Wands. “Overexpression of Human Aspartyl (Asparaginyl) β-Hydroxylase is associated with malignant transformation.” Cancer Research: 60, 1261-1266, 2000.